Protocol Ledger

NCT04864561 · Phase III · COMPLETED

COV-COMPARE Immunogenicity of Vaccine VLA2001 Compared to AZD1222

Interventional Phase III clinical trial protocol NCT04864561 sponsored by Valneva Austria in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-04-26 Enrollment: 4,034 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04864561
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)4,034 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04864561
Protocol FieldVerified Registry Value
NCT IdentifierNCT04864561
Consolidated Lead SponsorValneva Austria
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment4,034 participants (ACTUAL)
Registered Start Date2021-04-26
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04864561
Hospital Research SiteLocationSite Profile
University Hospitals Birmingham NHS Foundation TrustBirmingham, United KingdomOpen Hospital Dossier ->
Barts Health NHS TrustLondon, United KingdomOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI